Stock Market News
Jefferies ups AstraZeneca to 'buy', says it's at a 'turning point'
Jefferies upgraded AstraZeneca to 'buy' from 'hold' on Monday, lifting the price target to 5,600p from 5,075p as it said the pharmaceuticals giant is at a "turning point".
The bank said that accelerating new product launches and improving margins should deliver more than 20% core earnings per share growth in the mid-term.
"As one-off externalisation contributions decline core EPS quality is also improving, whilst the dividend once again becomes covered by the underlying business. Recovering growth, driven by the underlying business warrants a modest mid-term premium valuation."
Jefferies said several years of rebuilding the pipeline is now coming to fruition as new product launches build momentum.
After updating its model, the bank's mid-term revenue forecast is around 6% ahead of consensus.
"Our expectations for Lynparza, Brilinta, Farxiga and Fasenra are key drivers of this, reflecting the benefit of further indication expansion over the mid-term. Furthermore, over half the sales that we forecast to come from new and recently launched products between 2017A-22E, are generated by products that are already launched, or have already reported positive Phase III data, helping to de-risk expectations."
At 1530 GMT, the shares were up 0.3% to 34.71p.
The bank said that accelerating new product launches and improving margins should deliver more than 20% core earnings per share growth in the mid-term.
"As one-off externalisation contributions decline core EPS quality is also improving, whilst the dividend once again becomes covered by the underlying business. Recovering growth, driven by the underlying business warrants a modest mid-term premium valuation."
Jefferies said several years of rebuilding the pipeline is now coming to fruition as new product launches build momentum.
After updating its model, the bank's mid-term revenue forecast is around 6% ahead of consensus.
"Our expectations for Lynparza, Brilinta, Farxiga and Fasenra are key drivers of this, reflecting the benefit of further indication expansion over the mid-term. Furthermore, over half the sales that we forecast to come from new and recently launched products between 2017A-22E, are generated by products that are already launched, or have already reported positive Phase III data, helping to de-risk expectations."
At 1530 GMT, the shares were up 0.3% to 34.71p.
Related share prices |
---|
AstraZeneca (AZN) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price